Poland· PL-100038502
Erbitux
A cetuximab product containing cetuximabum, registered in Poland by Merck Europe B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Cetuximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FE01 (cetuximab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Cetuximab · ATC L01FE01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Cetuximabum
- Manufacturer
- Merck Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01FE01
- ATC class
- Cetuximab
- Defined daily dose
- 65 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990035922
- gtin05909990035946
- gtin05909990007509
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
18 interactions on record for cetuximab.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cetuximab · interactions on record
18 records
- 2 severe
- 16 moderate
Most severe, free to view
- Aminolevulinic acidL01XD04severe
- ThalidomideL04AX02severe
- OmeprazoleA02BC01moderate
- PantoprazoleA02BC02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cetuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandErbituxParanova Oy
- SwitzerlandErbitux
- CzechiaERBITUXMerck Europe B.V., Amsterdam
- BelgiumErbitux 5 mg/mlMerck Europe
- SpainERBITUX 5 MG/ML SOLUCION PARA PERFUSIONMerck Europe B.V.
- IcelandErbituxMerck Europe B.V.*
- NorwayErbituxMerck Europe B.V.
- SwedenErbitux 5 mg/ml Infusionsvätska, lösningMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Erbitux
- Liechtenstein · Erbitux
- Norway · Erbitux
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0ac78ff-4d76-4904-8897-1de33f163e64 GET /v1/drugs/c0ac78ff-4d76-4904-8897-1de33f163e64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "5 mg/ml",
"packaging": "05909990035922 ¦ Rpz ¦ EU/1/04/281/003 ¦ 34953\n1 fiol. 20 ml\n05909990035946 ¦ Rpz ¦ EU/1/04/281/005 ¦ 35026\n1 fiol. 100 ml\n05909990007509 ¦ Rpz ¦ Skasowane ¦ EU/1/04/281/001 ¦ 106980\n1 fiol. 50 ml",
"substance": "Cetuximabum 5 mg/ml",
"common_name": "Cetuximabum",
"pl_product_id": "100038502",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about cetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.